Posted on February 6th, 2009 by
Targeted therapies may be used in combination with other cancer treatments such as conventional chemotherapy.
Advances in science and technology have led to the development of several different types of targeted therapies, which target cancer through different mechanisms. These include targeted therapy for non-Hodgkin’s lymphoma.
Rituxan® (rituximab) is FDA approved for the treatment of certain types of non-Hodgkin’s lymphoma (NHL). Rituxan is a monoclonal antibody—a protein that fights cancer by binding to a portion of B-cells (which are cancerous in many forms of NHL) called the CD20 antigen. The binding action blocks cell activation and growth and may cause direct anticancer effects to the cell as well.
Benefits of Targeted Therapy
By focusing their effects on specific characteristics of cancer cells, targeted therapies provide effective cancer treatment with fewer side effects than conventional chemotherapy. Because targeted therapies are generally well tolerated, they can often be combined with other cancer therapies such as chemotherapy in order to improve treatment effectiveness.
Risks of Targeted Therapy
Though targeted therapies tend to cause less damage to normal cells than conventional chemotherapy or radiation therapy, there are some potential side effects. Talk with your doctor or read the prescribing information for more complete information about potential side effects.
Learn Whether Targeted Therapy Is Right for You
Determining whether a specific targeted therapy is appropriate for your cancer requires consideration of many factors, including the type, stage, and previous treatment. In addition, the specific characteristics of your cancer may need to be evaluated.
Copyright © 2010 CancerConsultants Non-Hodgkin's Lymphoma Information Center. All Rights Reserved.
Tags: Non-Hodgkin's Lymphoma
You must be logged-in to the site to post a comment.